Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash from Operations (2020 - 2025)

Barinthus Biotherapeutics' Cash from Operations history spans 6 years, with the latest figure at 4242000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 132.42% year-over-year to 4242000.0; the TTM value through Dec 2025 reached 47979000.0, down 65.79%, while the annual FY2025 figure was 47979000.0, 65.79% down from the prior year.
  • Cash from Operations reached 4242000.0 in Q4 2025 per BRNS's latest filing, up from 10726000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13086000.0 in Q4 2024 to a low of 19603000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 8742900.0, with a median of 10958500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: tumbled 1439.37% in 2021, then skyrocketed 688.9% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 7972000.0 in 2021, then crashed by 42.29% to 11343000.0 in 2022, then plummeted by 72.82% to 19603000.0 in 2023, then skyrocketed by 166.76% to 13086000.0 in 2024, then crashed by 132.42% to 4242000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Cash from Operations are 4242000.0 (Q4 2025), 10726000.0 (Q3 2025), and 18109000.0 (Q2 2025).